Featured Research

from universities, journals, and other organizations

Diabetes: Drug duo helps best, study finds

Date:
August 4, 2014
Source:
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health
Summary:
Metformin and SGLT2 inhibitors together reduce the blood sugar levels of diabetics considerably more effectively than either drug alone. Scientists report that this is due to a synergetic mechanism.

Metformin* and SGLT2 inhibitors** together reduce the blood sugar levels considerably more effectively than either drug alone. Scientists from the Helmholtz Zentrum München, partner in the German Center for Diabetes Research, report in the journal Diabetes that this is due to a synergetic mechanism.

Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012. Scientists headed by Dr. Susanne Neschen and Prof. Dr. Martin Hrabě de Angelis from the Helmholtz Zentrum München, in cooperation with Ludwig-Maximilians-Universität München and drug manufacturer Sanofi Aventis, have discovered how the two substances reinforce each other.

Medicinal chain reaction

SGLT2 inhibitors promote the elimination of sugar in the urine and consequently reduce the blood sugar. However, paradoxically the body reacts to this with increased sugar production in the liver. And this is where metformin comes in: it slows down the body's own sugar production. The interaction of the two substances causes a drop in blood sugar levels that is effective and prolonged, and the reduction is greater than with either substance administered on its own.

"Combination effective with minimal side effects"

"The combination of drugs effectively reduces the blood sugar, and particularly also the blood sugar peaks after meals. In diabetic mice, the double therapy produced an improvement in the long-term blood sugar level HbA1c within only two weeks," reports first author Neschen. "The duo consequently constitutes an effective treatment strategy for type 2 diabetes while also producing minimal side effects," adds Hrabě de Angelis. Type 2 diabetes is a metabolic disorder that affects around 6 million people in Germany, and that number is steadily increasing. The Helmholtz Zentrum München focuses on developing new approaches for the prevention, diagnosis and treatment of major widespread diseases.

Further Information

*Metformin: is the most frequently used oral antidiabetic agent and belongs to the biguanide class. Metformin increases the cells' sensitivity to insulin, particularly in the liver and muscles, so that more sugar is absorbed from the blood. It furthermore inhibits the production of sugar in the liver.

**SGLT2 Inhibitors: the substances block Sodium-Glucose-Transporter 2 and consequently inhibit the re-absorption of sugar filtered in the kidneys. This results in an increase in the excretion of sugar in the urine.


Story Source:

The above story is based on materials provided by Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Neschen, M. Scheerer, A. Seelig, P. Huypens, J. Schultheiss, M. Wu, W. Wurst, B. Rathkolb, K. Suhre, E. Wolf, J. Beckers, M. Hrabe de Angelis. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 (SGLT2) inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes, 2014; DOI: 10.2337/db14-0393

Cite This Page:

Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. "Diabetes: Drug duo helps best, study finds." ScienceDaily. ScienceDaily, 4 August 2014. <www.sciencedaily.com/releases/2014/08/140804100103.htm>.
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. (2014, August 4). Diabetes: Drug duo helps best, study finds. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/2014/08/140804100103.htm
Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. "Diabetes: Drug duo helps best, study finds." ScienceDaily. www.sciencedaily.com/releases/2014/08/140804100103.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) — Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) — Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) — A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) — The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins